大腸特異的ドラッグデリバリーのための製剤アプローチ:従来のナノキャリアシステムまで
Ashish Sriram Mishra1, Bhavna Ghosh2, Sivakumar Ponnurengam Malliappan3
1Department of Pharmaceutical Quality Assurance, SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur Chengalpattu 603203 Tamil Nadu India manimarv@srmist.edu.in.
RSC advances
|February 25, 2026
まとめ
大腸標的ドラッグデリバリーシステム(CDDS)は、製剤上の課題を克服することにより、大腸疾患の治療を改善することを目的としています。ナノテクノロジーを含む高度な戦略は、効果的な大腸薬物送達のための有望なソリューションを提供します。
背景:
- 大腸標的ドラッグデリバリーシステム(CDDS)は、IBD、IBS、大腸がんなどの大腸疾患の治療に不可欠です。
- 標的送達は、有効性を高め、副作用を減らし、患者のコンプライアンスを向上させます。
- 生理学的バリア(pH、微生物、酵素、通過時間)は、製剤上の大きな課題となります。
結論:
- 高度な製剤戦略、特にナノテクノロジーは、CDDSの課題を克服するための鍵となります。
- これらのシステムを臨床応用に移すには、さらなる研究が必要です。
- 改善されたCDDSは、より良い治療結果と患者のコンプライアンスにつながる可能性があります。
関連する概念動画
Modified-Release Drug Delivery Systems: Site-Targeted
45
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
45
Site-Targeted Drug Delivery Systems: Polymeric Carriers
57
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
57
Oral Drug Delivery Systems: Introduction
72
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
72
Bioavailability Enhancement: Drug Permeability Enhancement
266
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
266
Drug Delivery: Overview
999
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
999
Drug Delivery Systems: Different Types
92
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
92


